Male pill moves closer: first safety study completed
NCT ID NCT02754687
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 36 times
Summary
This early study tested a single dose of a new male hormone pill (11β-MNTDC) in 12 healthy men to see if it is safe and how the body handles it. The goal is to develop a daily oral contraceptive for men. This phase 1 trial focused on safety and side effects, not yet on preventing pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY MEN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
-
University of Washington
Seattle, Washington, 98195, United States
Conditions
Explore the condition pages connected to this study.